A Phase 4 interventional study of SUSTOL and SUSTOL kit components for administration in Chemotherapy-Induced Nausea and Vomiting (CINV), sponsored by Heron Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Heron Therapeutics · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing granisetron in Vomiting — none open to participants now, none under way, none of them phase 3. Granisetron · Vomiting.
Among the 25 studies testing granisetron in Vomiting, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 4, and was the 24th registered.
794 studies on the registry are indexed under Vomiting; 98 are open to participants now.
Browse Vomiting studies →None of the 25 studies testing granisetron in Vomiting is open now. The open studies under Vomiting, anywhere →
Granisetron: first FDA approval 1993 (KYTRIL), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 57 Vomiting studies recruiting now, 27 (47%) set no upper age limit and 24 (42%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 102 across 674 interventional studies indexed under Vomiting.
Median enrollment 60 across the 25 interventional studies. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 25 have an industry lead sponsor. The 10 most frequent:
Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 13 (87%) have results posted.
Heron Therapeutics has 3 studies filed under Vomiting — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing granisetron in Vomiting, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a repeat-dose, single-arm, open-label study that evaluated the potential impact of subject-reported injection-site reactions (ISRs) on activities of daily living (ADL) in adult subjects with cancer receiving SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV) for up to 4 sequential cycles of chemotherapy (Moderately Emetogenic Chemotherapy [MEC] or Anthracycline and Cyclophosphamide [AC] combination regimen).
This study was a post-marketing requirement (PMR) study with a planned sample size of 300 subjects. The Sponsor stopped the study upon release from the PMR, with 24 subjects having participated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SUSTOL® (granisetron) extended-release injection, for subcutaneous use
Drug: SUSTOL · Device: SUSTOL kit components for administration
Drug page: GranisetronStudies of GranisetronGranisetron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles. Supplied in commercially available SUSTOL kits.
Also known as: Granisetron extended-release injection for subcutaneous use
Each SUSTOL kit includes 1 sterile glass syringe containing 10 mg granisetron/0.4 mL, 1 sterile 18 Ga 5/8" special thin-walled administration needle, 2 sodium acetate syringe warming pouches, and 1 Point Lok needle protection device.
Number of Subjects With Severe Subject-reported ISRs With Significant Impact on ADL
Proportion of subjects with: • ISR of pain, itching, or swelling with a severity ≥7 AND ADL impact of ≥7 in any ADL domain (physical, social, work/household). OR • ISR of bleeding with ADL impact of ≥7 in any ADL domain (physical, social, work/household), AND 1 of the following: * Severity ≥7 and 4 to 6 bandage changes per day OR * ≥7 bandage changes per day OR * Urgent care/ER visit.
Time frame: Up to approximately 17 weeks: From the subject's first SUSTOL dose through the final study visit (28 days after the subject's last SUSTOL dose).
| Milestone | SUSTOL |
|---|---|
| Started | 24 |
| Completed | 18 |
| Not completed | 6 |
| Withdrew: Carboplatin shortage | 2 |
| Withdrew: Death | 1 |
| Withdrew: Noncompliance | 1 |
| Withdrew: Switch to maintenance treatment | 1 |
| Withdrew: Withdrawal by subject | 1 |
Proportion of subjects with: • ISR of pain, itching, or swelling with a severity ≥7 AND ADL impact of ≥7 in any ADL domain (physical, social, work/household). OR • ISR of bleeding with ADL impact of ≥7 in any ADL domain (physical, social, work/household), AND 1 of the following: * Severity ≥7 and 4 to 6 bandage changes per day OR * ≥7 bandage changes per day OR * Urgent care/ER visit.
| Participants | SUSTOL |
|---|---|
| Number of Subjects With Severe Subject-reported ISRs With Significant Impact on ADL | 1 |
Collected over Up to approximately 20 weeks: From the time the subject signed the Informed Consent Form through the final study visit (28 days after the subject's last SUSTOL dose).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SUSTOL | 1/24 (4.2%) | 5/24 (20.8%) | 0/24 (0%) |
| Event | SUSTOL |
|---|---|
| SepsisInfections and infestations | 1/24 |
| Septic shockInfections and infestations | 1/24 |
| COVID-19Infections and infestations | 1/24 |
| Chest painGeneral disorders | 1/24 |
| Breast abscessInfections and infestations | 1/24 |
| Deep vein thrombosisVascular disorders | 1/24 |
All subjects who received SUSTOL
| Age, Continuous(years) | SUSTOL |
|---|---|
| Mean | 55.6 ± 15.12 |
| Sex: Female, Male(Participants) | SUSTOL |
|---|---|
| Female | 15 |
| Male | 9 |
| Ethnicity (NIH/OMB)(Participants) | SUSTOL |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 23 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | SUSTOL |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | SUSTOL |
|---|---|
| United States | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2022 to primary completion in Sep 2023, 16 months.
Results were first posted in Nov 2026, 3 years 2 months after primary completion.
Of 42 phase 4 interventional studies under Vomiting, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 16 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Jul 2022 → May 2022, primary completion Oct 2025 → Sep 2023 and completion Oct 2025 → Sep 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Granisetron